{"id":54199,"date":"2024-07-17T10:25:40","date_gmt":"2024-07-17T08:25:40","guid":{"rendered":"https:\/\/ticker-noticiasep.microcontenidos.com\/NoticiaRSS.vbhtml?user=FRND562DLP&amp;cod=20240717102540"},"modified":"2024-07-17T10:25:40","modified_gmt":"2024-07-17T08:25:40","slug":"salud-grunenthal-announces-significant-investments-in-its-latin-america-production-sites","status":"publish","type":"post","link":"https:\/\/webciudadana.net\/?p=54199","title":{"rendered":"Salud: Gr\u00fcnenthal announces significant investments in its Latin America production sites"},"content":{"rendered":"\n<div><img decoding=\"async\" src=\"https:\/\/img.europapress.es\/fotoweb\/fotonoticia_20240717102540_300.jpg\" class=\"ff-og-image-inserted\"><\/div>\n<p>(Informaci\u00f3n remitida por la empresa firmante)<\/p>\n<p>\nGr\u00fcnenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients.<\/p>\n<p>\n\u00b7 Investment of more than \u20ac80 million to modernise Latin American production sites.<\/p>\n<p>\n\u00b7 In Santiago de Chile, a 3,500-square-metre solids plant has been completely refurbished, creating a world-class manufacturing facility with a production capacity of 1.8 billion tablets annually.<\/p>\n<p>\n\u00b7 In Quito, Ecuador, a new 1,800-square-metre plant will enable the production of 300 million high-quality tablets annually for pain patients in 17 European countries.<\/p>\n<p> NEWS AKTUELL \/\/ Aachen, Germany, 17 July 2024 &#8211; Gr\u00fcnenthal, a leading pharmaceutical company specializing in pain research and management, has announced significant investments in its Latin American production sites. These investments will enhance Gr\u00fcnenthal&#8217;s production network, ensuring a reliable supply of medicines for patients across Latin America, Europe, and beyond.<\/p>\n<p> Gr\u00fcnenthal operates a robust production network with five manufacturing sites in Germany, Switzerland, Italy, Chile, and Ecuador. These sites produce medicine from Gr\u00fcnenthal&#8217;s portfolio and offer contract manufacturing services to third parties. Gr\u00fcnenthal recently invested over \u20ac80 million to enhance its production capabilities in Latin America. To ensure production excellence and expand the geographical reach of its Latin American facilities, Gr\u00fcnenthal is implementing a standardized approach to product robustness, quality, and regulatory compliance across all its global manufacturing sites.<\/p>\n<p> \u00abOur investment in Latin America is a strong demonstration of our commitment to long-term competitiveness in the region,\u00bb says Victor Barbosa, Head of Global Operations and member of the Executive Board Team. \u00abFuture-proofing our manufacturing capabilities underscores our commitment to ensuring a safe, reliable, and efficient supply of medicine to patients globally. Gr\u00fcnenthal delivers high-quality medicine from Latin America to the world_a unique capability in the region.\u00bb<\/p>\n<p>\nGr\u00fcnenthal has been operating in Santiago de Chile for 45 years. The company&#8217;s largest manufacturing investment in the past three decades, a new 3,500-square-meter facility in Chile, will enable a production capacity of up to 1.8 billion tablets annually. This facility&#8217;s state-of-the-art technology reinforces Gr\u00fcnenthal&#8217;s position as Chile&#8217;s leading pharmaceutical manufacturer. Additionally, the advanced technology will positively impact employees by providing training and specialization, positioning them at the forefront of the industry. Gr\u00fcnenthal aims to complete the certification process with the European Medicines Agency (EMA) by November 2025, enabling the supply of medicines from Chile to Europe.<\/p>\n<p> Gr\u00fcnenthal&#8217;s manufacturing site in Quito, Ecuador, is one of the few in Latin America licensed to export to Europe and the only one in Ecuador with an EU Good Manufacturing Practice certificate, setting a high industry standard. The 50,000-square-metre campus is Ecuador&#8217;s largest and most modern manufacturing plant for solid, semi-solid, and liquid pharmaceuticals. Starting in 2025, the new facility will produce up to 300 million high-quality tablets annually for pain patients in 17 European countries.<\/p>\n<p> About Gr\u00fcnenthal<\/p>\n<p>\nGr\u00fcnenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better &#8211; and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain.<\/p>\n<p>\nGr\u00fcnenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Gr\u00fcnenthal employed around 4,400 people and achieved revenues of \u20ac1.8 billion.<\/p>\n<p> More information: https:\/\/www.grunenthal.com and Gr\u00fcnenthal Report 2023\/24<\/p>\n<p>\nFollow us on:<\/p>\n<p>\nLinkedIn: Gr\u00fcnenthal Group<\/p>\n<p>\nInstagram: Gr\u00fcnenthal<\/p>\n<p>\nMedia Contact:<\/p>\n<p>\nJessica Liu, Global Corporate Affairs &amp; Communication <\/p>\n<p>\nEmail: jessica.liu@grunenthal.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Informaci\u00f3n remitida por la empresa firmante) Gr\u00fcnenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients. \u00b7 Investment of more than \u20ac80 million to modernise Latin American production sites. \u00b7 In Santiago de Chile, a 3,500-square-metre solids plant has been completely refurbished, creating a world-class manufacturing facility with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-54199","post","type-post","status-publish","format-standard","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/54199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54199"}],"version-history":[{"count":0,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/54199\/revisions"}],"wp:attachment":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}